Compare AVNT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNT | EWTX |
|---|---|---|
| Founded | 1927 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | 2000 | 2021 |
| Metric | AVNT | EWTX |
|---|---|---|
| Price | $36.30 | $31.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $41.50 | $37.38 |
| AVG Volume (30 Days) | 691.7K | ★ 741.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $3,835,500,000.00 | N/A |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $3.39 | N/A |
| P/E Ratio | $39.99 | ★ N/A |
| Revenue Growth | ★ 1.71 | N/A |
| 52 Week Low | $27.48 | $10.60 |
| 52 Week High | $44.85 | $32.80 |
| Indicator | AVNT | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 58.39 |
| Support Level | $35.07 | $28.72 |
| Resistance Level | $38.15 | N/A |
| Average True Range (ATR) | 1.07 | 1.46 |
| MACD | 0.32 | 0.11 |
| Stochastic Oscillator | 92.35 | 73.03 |
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.